| abstract |
The present disclosure provides methods for treating a human patient diagnosed with cancer, the methods comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) adding The patient uses at least an initial dose of about 0.1 mg of the PRMT5 inhibitor per day and continues for an initial dosing cycle of about 5 to about 21 days, the PRMT5 inhibitor being (1S, 2R, 3S, 5R)-3- (2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane- 1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof; and (ii) administering to the patient at least a subsequent dose of the PRMT5 inhibitor of at least about 0.1 mg per day for one or more of each of Subsequent dosing cycles of about 5 to about 21 days. In these methods, the first subsequent dosing cycle is at least about 5 days apart from the initial dosing cycle, and the subsequent dosing cycles are at least about 5 days apart from each other. |